At Least Three Bidders Reach Level Two | Merck-Sanofi Merial JV Divestitures

On Monday, I asked after the plain delay in getting the bidders through to the next round, here — and whether that would push back the timeline for completing the overall reconstituted 50-50 joint venture between Merck and Sanofi-Avenits.

Today, as if on cue — Reuters obliges, with an update — do go read it all:

. . . .Merck and its French partner Sanofi are creating a powerhouse in veterinary drugs and vaccines, with $5.3 billion in sales and almost a third of the global market. But they have to sell some product lines to allay competition concerns.

The duo are merging Sanofi’s pet-focused Merial unit, which they once jointly owned, with Merck’s bigger, livestock-oriented Intervet business, relegating Pfizer to second place in the $19 billion animal health industry.

The divestment of some of these assets offers smaller players a chance to bulk up.

But several industry experts have said that the deal is likely to be just a prelude to more consolidation in the sector. . . .

That much is certainly true — we’ll keep you posted.


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s